Quicksilver Scientific

Free shipping over $50    Expect shipping delays due to holiday volume


Unsupported Browser

This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

PushCatch® Liver Detox References

  1. Grand D.M. Detoxification pathways in the liver. J Inherit Metab Dis. 1991; 14(4): 421-430.
  2. Leslie EM, et al. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005; 204(3): 216-237.
  3. Zamek-Gliszczynski MJ, et al. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and GSH metabolites. Eur J Pharm Sci. 2006; 27(5): 447-486.
  4. Trauner M, et al. Bile salt transporters: Molecular characterization, function, and regulation. Physiol Rev. 2003; 83(2): 633-671.
  5. Nguyen T, et al. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009; 284(20): 13291-13295.
  6. Ganey PE, et al. Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents. Toxicology. 2001; 169(3): 195-208.
  7. Urdaneta V and Casadesus J. Interactions between bacteria and bile salts in the gastrointestinal and hepatobiliary tracts. Front Med (Lausanne). 2017; 4: 163.
  8. Islam KB, et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterol. 2011; 141(5): 1773-1781.
  9. Inagaki T, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA. 2006; 103(10): 3920-3925.
  10. Sadiq FA, et al. Lactic acid bacteria as antifungal and anti‐mycotoxigenic agents: A comprehensive review. Comp Rev Food Sci Food Saf. 2019; 18(5): 1403-1436.
  11. Kinoshita H. Biosorption of heavy metals by lactic acid bacteria for detoxification. Methods Mol Biol. 2019; 1887: 145-157.
  12. Li C, et al. Screening for Lactobacillus plantarum strains that possess organophosphorus pesticide-degrading activity and metabolomic analysis of phorate degradation. Front Microbiol. 2018; 9: 2048.
  13. Kalitsky-Szirtes J, et al. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos. 2004; 32(1): 20-27.
  14. Awad WA, et al. Enteric pathogens and their toxin-induced disruption of the intestinal barrier through alteration of tight junctions in chickens. Toxins (Basel). 2017; 9(2).
  15. Yu Y, et al. Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways. Biochem Pharmacol. 2015; 97(2): 173-177.
  16. Shaik F.A., et al. Bitter taste receptors: Extraoral roles in pathophysiology. Int J Biochem Cell Biol. 2016; 77(Pt B): 197-204.
  17. Lee RJ and Cohen NA. The emerging role of the bitter taste receptor T2R38 in upper respiratory infection and chronic rhinosinusitis. Am J Rhinol Allergy. 2013; 27(4): 283-286.
  18. Gaida MM, et al. Sensing developing biofilms: The bitter receptor T2R38 on myeloid cells. Pathog Dis. 2016; 74(3).
  19. Tang X, et al. Target profiling analyses of bile acids in the evaluation of hepatoprotective effect of gentiopicroside on ANIT-induced cholestatic liver injury in mice. J Ethnopharmacol. 2016; 194(24): 63-71.
  20. Mirzaee F, et al. Medicinal, biological and phytochemical properties of Gentiana species. J Tradit Complement Med. 2017; 7(4): 400-408.
  21. Gonzalez-Castejon M, et al. Diverse biological activities of dandelion. Nutr Rev. 70(9): 534-547.
  22. Liu B, et al. Taraxasterol inhibits LPS-induced inflammatory response in BV2 microglia cells by activating LXRα. Front Pharmacol. 2018; 9: 278.
  23. Esatbeyoglu T, et al. Sesquiterpene lactone composition and cellular Nrf2 induction of Taraxacum officinale leaves and roots and Taraxinic Acid β-d-Glucopyranosyl Ester. J Med Food. 2017; 20(1): 71-78.
  24. Chodera A, et al. Effect of flavonoid fractions of Solidago virgaurea L on diuresis and levels of electrolytes. Acta Pol Pharm. 1991; 48(5-6): 35-37.
  25. Apati P, et al. In-vitro effect of flavonoids from Solidago canadensis extract on glutathione S-transferase. J Pharm Pharmacol. 2006; 58(2): 251-256.
  26. Deng R, et al. The hypolipidemic agent guggulsterone regulates the expression of human bile salt export pump: dominance of transactivation over farnesoid X receptor-mediated antagonism. J Pharmacol Exp Ther. 2007; 320(3): 1153-1162.
  27. Sarup P, et al. Pharmacology and phytochemistry of oleo-gum resin of Commiphora wightii (Guggulu). Scientifica (Cairo). 2015; 2015: 138039.
  28. Crocenzi FA, et al. Silymarin as a new hepatoprotective agent in experimental cholestasis: New possibilities for an ancient medication. Curr Med Chem. 2006; 13(9): 1055-1074.
  29. Abenavoli L, et al. Milk thistle in liver diseases: Past, present, future. Phytother Res. 2010; 24(10): 1423-1432.
  30. Gu M, et al. Silymarin ameliorates metabolic dysfunction associated with diet-induced obesity via activation of farnesyl X receptor. Front Pharmacol. 2016; 7: 345.
  31. Crocenzi FA, et al. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: A study in vivo and in isolated hepatocyte couplets. Hepatology. 2001; 34(2): 329-339.
  32. Suh JH, et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci USA. 2004; 101(10): 3381-3386.
  33. Arredondo F, et al. After cellular internalization, quercetin causes Nrf2 nuclear translocation, increases glutathione levels, and prevents neuronal death against oxidative insult. Free Radic Biol Med. 2010; 49(5): 738-747.
  34. Saw CL, et al. Pharmacodynamics of dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug-metabolizing and antioxidant genes and synergism with isothiocyanates. Biopharm Drug Dispos. 2011; 32(5): 289-300.
  35. Micek J, et al. Quercetin and its anti-allergic immune response. Molecules. 2016; 21(5).
  36. Seelinger G, et al. Anti-oxidant, anti-inflammatory, and anti-allergic activities of luteolin. Planta Med. 2008; 74(14): 1667-1677.
  37. Suzuki T and Hara H. Quercetin enhances intestinal barrier function through the assembly of zonula occludens-2, occludin, and claudin-1 and the expression of claudin-4 in caco-2 cells. J Nutr. 2009; 139(5): 965-974.
  38. Mohammedelnour AA, et al. Effect of solvent types on phenolics content and antioxidant activities of Acacia polyacantha gum. Int Food Res J. 2017; 24: Suppl S369-S377.
  39. Liu G, et al. Chitosan modulates inflammatory responses in rats infected with enterotoxigenic Escherichia coli. Med Inflamm. 2016; 7432845.
  40. Vaziri ND, et al. Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption. Am J Nephrol. 2013; 37: 518-525.
  41. Sanchez A, et al. Influence of preparation methods of chitooligosaccharides on their physiochemical properties and their anti-inflammatory effects in mice and in RAW 264.7 macrophages. Mar Drugs. 2018; 16(11).
  42. Langmead L, et al. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther. 2004; 19(5): 521-527.
  43. Im SA, et al. In vivo evidence of the immunomodulatory activity of orally administered Aloe vera gel. Arch Pharm Res. 2010; 33(3): 451-456.
  44. Cherbut C, et al. Acacia gum is a Bifidogenic dietary fibre with high digestive tolerance in healthy humans. Microb Ecol Health Dis. 2003; 15(1): 43-50.
  45. Suthongsa S, et al. Effects of dietary levels of chito-oligosaccharide on ileal digestibility of nutrients, small intestinal morphology, and crypt cell proliferation in weaned pigs. Livest Sci. 2017; 198: 37-44.
  46. Neuvonen PJ and Olkkola KT. Oral activated charcoal in the treatment of intoxications: Role of single and repeated doses. Med Toxicol. 1988; 3: 33-58.
  47. Bhatti SA, et al. Protective role of bentonite against aflatoxin B1- and ochratoxin A-induced immunotoxicity in broilers. J Immunotoxicol. 2017; 14(1): 66-76.
  48. Li X, et al. Carbohydrate functionalized chitosan fiber for influenza virus capture. Biomacromolecules. 2011; 12: 3962-3969.
  49. Guan G, et al. Biological effects and applications of chitosan and chito-oligosaccharides. Front Physiol. 2019; 10.3389/fphys.2019.00516.
  50. Vighi G, et al. Allergy and the gastrointestinal system. Clin Exp Immunol. 2008; 153(Suppl 1): 3-6.
  51. Fukui H. Increased intestinal permeability and decreased barrier function: Does it really influence the risk of inflammation? Inflamm Intest Dis. 2016; 1(3): 135-145.
  52. Salguero MV, et al. Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease. Exp Ther Med. 2019; 18(5): 3461-3469.
  53. Aguiniga LM, et al. Lipopolysaccharide domains modulate urovirulence. Infect Immun. 2016; 84(11): 3131-3140.
  54. Ebersole JL, et al. Systemic endotoxin levels in chronic indolent periodontal infections. J Periodontal Res. 2010; 45(1): 1-7.
  55. Hartmann G, et al. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002; 303(1): 273-281.
  56. Bolder U, et al. Hepatocyte transport of bile acids and organic anions in endotoxemic rats. Impaired uptake and secretion. Gastroenterology. 1997; 112: 214-225.
  57. Cherrington NJ, et al. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab Dispos. 2004; 32(7): 734-741.
  58. Tang W, et al. Endotoxin downregulates hepatic expression of P-glycoprotein and MRP2 in 2-acetylaminofluorene-treated rats. Mol Cell Biol Res Commun. 2000; 4(2): 90-97.
  59. Ditter B, et al. Ability of various adsorbents to bind endotoxins in vitro and to prevent orally induced endotoxemia in mice. Gastroenterology. 1983; 84(6): 1547-1552.
  60. Khalid J, et al. Medical and environmental applications of activated charcoal: Review article. Eur Sci J. 2015; 11(3): 50-56.
  61. Karnib M, et al. Heavy metals removal using activated carbon, silica and silica activated carbon composite. Energy Procedia. 2014; 50: 113-120.
  62. Du XN, et al. Effect of activated charcoal on endotoxin adsorption. Part I. An in vitro study. Biomater Artif Cells Artif Organs. 1987; 15(1): 229-235.
  63. Zellner T, et al. The use of activated charcoal to treat intoxications. Dtsch Arztebl Int. 2019; 116(18): 311-317.
  64. Krasopoulos JC, et al. The adsorption of bile salts on activated carbon. Lipids. 1980; 15(5): 365-370.
  65. Musso CG et al. Combination of oral activated charcoal plus low protein diet as a new alternative for handling in the old end-stage renal disease patients. Saudi J Kidney Dis Transpl. 2010; 21(1): 102-104.
  66. Koide SS. Chitin-chitosan: Properties, benefits, and risks. Nutrition Research. 1998; 8(6): 1091-1101.
  67. Lutjohann D, et al. Influence of chitosan treatment on surrogate serum markers of cholesterol metabolism in obese subjects. 2018; 10(1): 72.
  68. Trivedi VR, et al. Single-blind, placebo-controlled randomized clinical study of chitosan for body weight reduction. Nutr J. 2015; 15(3).
  69. Xiao D, et al. Effects of dietary administering chitosan on growth performance, jejunal morphology, jejunal mucosal sIgA, occludin, claudin-1 and TLR4 Expression in weaned piglets challenged by enterotoxigenic Escherichia coli. Int Immunopharmacol. 2013; 17(3): 670-676.
  70. Chkuaseli A, et al. Application of new mycotoxin adsorbent-bentonite clay “Askangel” in poultry feed. Ann Agr Sci. 2016; 14(4): 295-298.
  71. Haydel SE, et al. Broad-spectrum in vitro antibacterial activities of clay minerals against antibiotic-susceptible and antibiotic-resistant bacterial pathogens. J Antimicrob Chemother. 2008; 61(2): 353-361.
  72. Schaumberger S, et al. Evaluation of the endotoxin binding efficiency of clay minerals using the Limulus Amebocyte lysate test: An in vitro study. B. Express. 2014; 4: 1.
  73. Zhao W, et al. Thiol-functionalized mesoporous silica for effective trap of mercury in rats. J Nanomater. 2016; Article ID: 9758264.
  74. Pressman P, et al. Aloe vera at the frontier of glycobiology and integrative medicine: Health implications of an ancient plant. Sage Open Med. 2019; 7.
  75. Quezada MP, et al. Acemannan and fructans from Aloe vera (Aloe barbadensis Miller) plants as novel prebiotics. J Agric Food Chem. 2017; 65(46): 10029-10039.
  76. Hekmatpou D, et al. The effect of Aloe vera clinical trials on prevention and healing of skin wound: A systematic review. Iran J Med Sci. 2019; 44(1): 1-9.
  77. Hes M, et al. Aloe vera (L.) Webb.: Natural sources of antioxidants – A review. Plant Foods Hum Nutr. 2019; 74(3): 255-265.
  78. Calame W, et al. Gum arabic establishes prebiotic functionality in healthy human volunteers in a dose-dependent manner. Br J Nutr. 2008; 100(6): 1269-1275.
  79. Babiker R, et al. Effect of Gum Arabic (Acacia Senegal) supplementation on visceral adiposity index (VAI) and blood pressure in patients with type 2 diabetes mellitus as indicators of cardiovascular disease (CVD): a randomized and placebo-controlled clinical trial. Lipids Health Dis. 2018; 17: 56.
  80. Daguet D, et al. Acacia gum improves the gut barrier functionality in vitro. Agro Food Industry Hi Tech. 2015; 26(4): 29-33.
  81. Daguet D, et al. Arabinogalactan and fructooligosaccharides improve the gut barrier function in distinct areas of the colon in the Simulator of the Human Intestinal Microbial Ecosystem. J Fuct Foods. 2016; 20: 369-379.
  82. Spector AA and Yorek MA. Membrane lipid composition and cellular function. J Lipid Res. 1985; 26(9): 1015-1035.
  83. Porter CJ. Drug delivery to the lymphatic system. Crit Rev Ther Drug Carrier Syst. 1997; 14(4): 333-393.
  84. Ahn H and Park JH. Liposomal delivery systems for intestinal lymphatic drug transport. Biomater Res. 2016; 20: 36.
  85. Alyautdin R, et al. Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine. 2014; 9: 795-811.
Your Cart